242 / 245
242
· DOS Abstracts
Quantitative Bone Mineral Changes Evaluated by
DEXA after Bone Defect Reconstruction using a
Biphasic Bone Graft Substitute after Intralesional
Curettage in Benign Bone Tumors or Cysts
Peter Horstmann, Werner Hettwer, Michael Mørk Petersen
Department of Orthopedics, Muskuloskeletal Tumor Section, Rigshospitalet,
University of Copenhagen, Denmark
Background:
Non-invasive evaluation of changes in mineralization after cu-
rettage is not always easy using conventional x-rays. Precise and quantitative
measurements of bone mineral density (BMD) and bone mineral content (BMC)
at various skeletal sites can be performed using DEXA.
Purpose / Aim of Study:
To document early changes in BMD in patients re-
ceiving bone defect reconstruction with a biphasic (60% calcium sulfate/ 40%
calcium phosphate) bone graft substitute (BGS) after intralesional curettage in
benign bone tumors and cysts.
Materials and Methods:
We prospectively reviewed 8 patients (F/M: 3/5,
mean age 40 (18-68) years) who underwent intralesional curettage of 9 be-
nign bone tumors or cysts with subsequent bone defect reconstruction with a
biphasic BGS (CERAMENT™|BONE VOID FILLER) or a biphasic gentamicin elut-
ing BGS (CERAMENT™|G) at our orthopedic oncology center with a minimum
of 6 months follow-up.
Findings / Results:
The most commonly treated lesions were uni- or multi-
cameral bone cysts (n=3) and enchondromas (n=3) with an average size of
17 (6-33) mL. The most commonly affected regions were the proximal femur
(n=3), and the proximal humerus (n=2). CERAMENT™|BVF was used in 6 cases
and CERAMENT™|G was used in 3 cases with an average amount of 17 (4-56)
mL. The mean postoperative BMD was 2.70 g/cm2 (CI95%: 2.11- 3.30), 1.44
g/cm2 (CI95%: 1.14-1.76) at 6 weeks, 1.28 g/cm2 (CI95%: 0.94- 1.61) at 3
months, and 1.21 g/cm2 (CI95%: 0.84-1.58) at 6 months.
Conclusions:
In this small prospective series of 8 patients receiving bone de-
fect reconstruction with a biphasic bone graft substitute (60% calcium sulfate/
40% calcium phosphate), we found that the BMD at the defect site decreases
in the first three months, probably corresponding to the resorption of calcium
sulfate, without any further significant decrease from 3 to 6 months.
Conflicts of Interest
Peter Horstmann; funded by BONESUPPORT AB
Werner Hettwer; BONESUPPORT AB
193.